Zohaib Ahmed

Zohaib Ahmed

Auto-generated profile, based on publicly available information

Zohaib Ahmed

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Leukemia Research
Verified
Journal Article
Closed access
JYJames Yu
James Yu
YDYuan Du
Yuan Du
AJAnum Jalil
Anum Jalil
ZAZohaib Ahmed
Zohaib Ahmed
SMShahram Mori
Shahram Mori
CCChung-Che Chang
Chung-Che Chang

1 June 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MGMengni Guo
Mengni Guo
JLJieying Liu
Jieying Liu
ZAZohaib Ahmed
Zohaib Ahmed
JYJames Yu
James Yu
RMRuoyu Miao
Ruoyu Miao
TMTarek Mekhail
Tarek Mekhail
2525 Background: Immune checkpoint inhibitors (ICIs) can cause a variety of inflammatory autoimmune tissue damage, referred to as immune-related adverse events (irAEs). COVID-19 is associated with increased amounts of proinflammatory cytokines, which may synergistically affect the outcome of irAEs. Data are limited regarding the impact of COVID-19 on irAEs in ICI-treated cancer patients. Methods: We retrospectively analyzed adult patients with malignant solid tumors treated with ICIs at AdventHealth Orlando between August 2020 and August 2021. All COVID-19 infections were confirmed by PCR. Patients who had the most recent ICI treatment over one month before or after the positive COVID-19 test were excluded from the study. For COVID-19 positive group, only the irAEs that developed after COVID-19 infection were considered as events. Results: A total of 579 patients were included in our study, with 46 (7.9%) in COVID-19 positive group, and 533 (92.1%) in COVID-19 negative group. The baseline characteristics of patients in the two groups were similar in terms of age, ethnicity, ECOG, cancer histology, and type of ICI. With a median follow-up of 10 months (1-73 months), no differences in the time from ICI initiation to irAE onset, corticosteroid use, or additional immunosuppressant use were seen. A trend in higher incidence of all-grade diarrhea/colitis (8.7% vs. 3.0%, p=0.07) and grade 3 and 4 hepatitis (4.3% vs. 0.8%, p=0.08) was noted in the COVID-19 positive group, however the difference was not statistically significant. No significant difference in the incidence of pneumonitis (2.2% vs. 1.1%, p=0.44), nephritis (2.2% vs. 0.8%, p=0.34) or dermatitis (6.5% vs. 6.4%, p=1.00) were noted between COVID-19 positive and negative groups. We noticed a higher incidence of all-grade irAEs in the COVID-19 positive group (30.4% vs. 19.9%, p=0.18), but the difference was not statistically significant. The incidence of grade 3 and 4 irAEs was significantly higher in the COVID-19 positive group (10.9% vs. 3.2%, p=0.02). Nine COVID-19 related death occurred while no irAE-related death was noted in the entire cohort. Conclusions: Our study suggested that COVID-19 may pose a risk of severe irAEs in cancer patients receiving ICIs. Close monitoring and possible delaying ICI administration could be considered when cancer patients were infected with COVID-19. [Table: see text]

3 February 2026 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
ZAZohaib Ahmed
Zohaib Ahmed
WHWalid Hamouche
Walid Hamouche
SASyed O. Ahmad
Syed O. Ahmad
JYJames Yu
James Yu
RCRaad Chowdhury
Raad Chowdhury
ONOmar Nadeem
Omar Nadeem